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a b s t r a c t
Gene therapy has a wide range of applications for various types of pathologies. Viral methods of gene
delivery provide high levels of gene expression but have various safety concerns. Non-viral methods
are largely known to provide lower levels of expression. We aim to address this issue by using plasmid
DNA with smaller backbones to increase gene expression levels when delivered using non-viral methods.
In this study we compare gene expression levels between two vectors with firefly luciferase encoding
gene insert using liposome complexes and gene electrotransfer as delivery methods. A 2-fold reduction
in plasmid vector backbone size, disproportionately enhanced gene expression levels more than 10fold in rat tenocytes in vitro, and rat myocardium in vivo, while improvements in delivery to the skin were
more moderate.
Ó 2021 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

1. Introduction
Gene therapy has a wide variety of applications that have
reached the clinical use for some applications [1]. These applications include treating cancer, genetic diseases, cardiovascular disease, neurological disorders, opthalmic and infectious diseases
[1]. Current gene therapy clinical trials are largely composed of
studies that use viral vectors as a method for gene delivery [1].
While viral vectors as a delivery method are generally regarded
as efficient, there are many safety concerns related to using viral
vectors, namely insertional mutagenesis [1]. Non-viral gene delivery methods, such as plasmid DNA (pDNA) injection, gene gun,
electroporation (also called gene electrotransfer, or GET), and liposome complexes are generally seen as safer, but also less efficient
when compared to viral vectors [2]. We aim to improve gene
expression when using non-viral delivery methods by using a
unique, smaller pDNA backbone that is specifically designed to
induce high gene expression.
pDNA consists of two main parts: an expression cassette, which
contains the transgene and regulatory sequences, and the bacterial
backbone, which is used largely in the production of pDNA, often
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containing restriction sites and an antibiotic resistance marker
[3]. Components of both the expression cassette and the bacterial
backbone can affect gene expression [3,4]. Within the expression
cassette, regulatory sequences such as the promoter, intron(s),
and terminator can affect gene expression [3,4]. The inclusion of
the bacterial backbone in pDNA has been seen to negatively affect
expression when comparing pDNA to minicircles; however certain
components of the bacterial backbone may affect expression more
than others [3,4]. The length of the spacer region has been found to
be particularly important, as spacer regions over 1000 base pairs
(bp) have been found to induce transgene silencing [5]. Lu et al.
[5] hypothesized that this may be due to the position of the 50
end of promoter and the 30 end of terminator regions in relation
to gene looping, which has been shown to promote transcription,
primarily by reusing RNA polymerase II molecules from the terminator to the promoter region [6]. Hornstein et al. later investigated
cell entry and found that pDNA cell entry was not related to vector
size, and similarly proposed that DNA-protein interaction may
instead be the cause of smaller plasmids generally producing
enhanced gene expression [7]. Hornstein et al. [7] hypothesize that
although transcription proteins are more likely to bind to longer
DNA, the one-dimensional movement of RNA polymerase is limited by the length of the DNA and may dissociate before reaching
the plasmid’s expression cassette [8].

https://doi.org/10.1016/j.bioelechem.2021.107981
1567-5394/Ó 2021 The Authors. Published by Elsevier B.V.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Enhancement of gene expression by using shorter pDNA
sequences has been observed both in vitro and in vivo. Previous
studies have shown that decreasing plasmid backbone size
enhances transgene expression when using GET both in HeLa cells
[7] and in mice [9]. Additionally, minicirles, which do not have a
bacterial backbone, typically provide higher expression than conventional pDNA, however scalability and quality control remain
problematic [3,10]. These findings served as motivation to investigate potential differences in gene expression between two different commercially available plasmids.
Our in vivo experiments use GET as a method of non-viral gene
delivery. Generally, the field has explored a wide variety of pulsing
conditions to be used in different applications [11]. Work has also
been done to optimize pulsing conditions for delivery to specific
tissues, including several of our and other researchers’ previous
work to deliver pDNA to both skin and heart tissues [12–16]. While
our pulsing conditions are based primarily on these previous findings, we also test additional parameters within this study. It has
been previously established that lower voltages [17] and biphasic
pulsing conditions [18,19] can reduce muscle twitching. Additionally, lower voltages can also reduce tissue damage [17]. For these
reasons, we also test pulsing conditions that are biphasic, as well
as conditions that have lower voltages than what has been previously established to induce transgene expression.
In this study, we compare the gWiz (traditional plasmid) and
NTC9385R (NanoplasmidTM) vectors with a reporter gene insert
encoding firefly luciferase tagged with the c-myc and DDK tags
by analyzing gene expression in rat tenocytes, as well as gene
delivery to the skin and ventricular myocardium in a small animal
model.

1.7 kb. The final overall sizes of the constructs used in this study
are 6.8 kb and 3.6 kb respectively. Additionally, the spacer region
is 2,678 bp in the gWiz vector and 454 bp in the NTC9385R vector
[20]. In addition, gWiz-GFP was used in the in vitro transfection,
which includes a reporter gene encoding for green fluorescent protein. Plasmid DNA was suspended in sterile saline at 2 mg/mL.
Endotoxin levels in both plasmids were <0.1 EU/lg plasmid, confirmed by Aldevron and Nature Technologies. Plasmid DNA maps
are shown in Fig. 1.
2.2. Gene electrotransfer in vitro
Primary rat tenocytes were transfected using transfection
reagent Trans-ITÒ-LT1 by Mirus Bio (Madison, WI). Cells were
seeded at a density of 5  104 cells per well in a 6-well plate and
incubated for 24 h. The transfection was then completed according
to the manufacturer’s protocol, using 7.5 mg TransITÒ-LT1 reagent
and 1.25 ml respective pDNA per well, keeping the pDNA of equal
mass. Three different plasmids were used: gWiz-Luc-Myc-DDK
(n = 2), NTC9385R-Luc-Myc-DDK (n = 2), and gWiz-GFP (n = 2).
The gWiz-GFP transfection tenocytes were observed under a fluorescent microscope every 24 h to estimate optimal incubation time
(typically 24–72 h) for the greatest number of expressing cells. The
plate was read and cells were fixed at 72 h.
For the equimolar experiment, B16F10 melanoma cells were
transfected using transfection reagent Trans-ITÒ-LT1 by Mirus Bio
(Madison, WI). Cells were seeded at a density of 5  104 cells per
well in a 6-well plate and incubated for 24 h. To do the equimolar
transfection, we calculated the ratio of the molecular weights of
the two plasmids as follows:
4.22  106g/mol gWiz-Luc-Myc-DDK: 2.21  106 g/mol
NTC9385R-Luc-Myc-DDK
=
1.908
gWiz-Luc-Myc-DDK:
NTC9385R-Luc-Myc-DDK

2. Materials and methods
2.1. Plasmids

Therefore, 1.25 ml pDNA for the NanoplasmidTM (n = 3) and
2.39 ml pDNA of traditional plasmid group (n = 3) at 2mg/ml were
used per transfection. The plate was read, and cells were fixed at
72 h.

Plasmids used in this study are gWiz-Luc (Aldevron, Fargo, ND)
further tagged with myc and DDK tags (gWiz-Luc-Myc-DDK) and
NTC9385R-Luc-Myc-DDK (Nature Technologies Corporation, Lincoln, NE). In this context, luc represents the firefly luciferase reporter gene, and myc and DDK represent the c-myc and DYKDDDDK
(or FLAG) tags respectively. These tags are polypeptides that allow
for easier detection of cells expressing our transgene in our
immunofluorescence analysis. This transgene was inserted into
two different vectors: gWiz and NTC9385R. The transgene insert
was kept consistent between the two constructs (1.8 kilobases,
or kb). The gWiz vector is 5.0 kb and the NTC9385R vector is

A

2.3. Animals
Male Sprague Dawley rats initially weighing 250–300 g
obtained from Charles River Laboratories (Wilmington, MA) were
used for these studies. All animal studies followed an approved
Old Dominion University Institutional Animal Care and Use Com-
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Fig. 1. Plasmid DNA Maps. NTC9385R-Luc-Myc-DDK or Nanoplasmid (A) and gWiz-Luc-Myc-DDK or traditional plasmid (B).
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for high expression in the myocardium with traditional plasmid.
Lower voltage is known to reduce potential tissue damage

mittee protocol, in accordance with the Guide for the Care and Use
of Laboratory Animals at an AAALAC accredited facility. Rats were
acclimated for 48 h before any procedures were conducted.

2.6. Bioluminescence analysis
2.4. Gene electrotransfer to the rat skin
Tenocytes were imaged at 72 h using the In Vivo Imaging System(IVIS (PerkinElmer, Waltham, MA))[1] to quantify gene expression via the bioluminescence levels detected from the luciferaseluciferin reaction. D-luciferin (Gold Bio, St. Louis, MO) was added
to fresh media at a concentration of 150 lg/mL as recommended
by the manufacturer. Images were taken immediately after adding
the luciferin until the peak flux values for each group were
observed. A circular region of interest (ROI) was used to get flux
values for individual wells. ROI diameter was kept consistent
among wells. B16F10 cell bioluminescence was quantified with a
luminescence plate reader after D-luciferin addition to the media
(Fig. 2A, 2E and Supplemental Fig. 1 Figure Supplementary Fig. 1).
Animals from the gene delivery to the skin experiment were
imaged to measure bioluminescence levels using the IVIS at 24
and 48 h after GET. Animals were anesthetized with 3% isoflurane
and given subcutaneous injections of D-luciferin at a concentration
of 150 mg luciferin/kg body weight. Animals were imaged approximately every 5 min, alternating flanks. Once peak bioluminescence levels were reached for each treatment site, animals were
returned to their cages and observed until they were fully recovered from anesthesia. Circular ROIs were used to examine individual treatment sites. ROI diameter was kept consistent among sites
and for all animals.
Animals from the gene delivery to the heart experiment were
imaged to measure bioluminescence levels using the IVIS at 24
and 48 h after GET. Animals were anesthetized with 3% isoflurane
and given subcutaneous injections of D-luciferin at a concentration
of 150 mg luciferin/kg body weight. Animals were imaged approximately every 5 min. Once peak bioluminescence levels were
reached for each treatment site, animals were returned to their
cages and observed until they were fully recovered from anesthesia. A circular ROI was used to examine the area containing the bioluminescent signal from the heart. ROI diameter was kept
consistent among animals.

Treatment sites on each flank were randomly assigned to the
traditional plasmid, NanoplasmidTM, and injection-only (IO) groups.
Each animal had 4 treatment sites per flank (8 treatment sites per
animal). After thorough hair clipping of each flank, a conductive
electrode gel was placed on the skin to facilitate contact with the
grounding plate. Each treatment site then received a 50 ll injection
of 2 mg/mL pDNA. A custom-built pulser was used to administer
pulses to the skin, capable of biphasic pulses in the 1 microsecond
range. A platinum tweezer electrode with a 5 mm diameter (BTX,
Holliston, MA) and a 2 mm gap was used to deliver pulses to each
treatment site. There were 5 different pulsing conditions were
administered, consisting of the conditions shown in Fig. 3. Group
1, delivering 8 pulses at 40 V applied voltage and 150 ms pulse
length acted as a positive control, as we had previously observed
gene expression in the skin using a similar condition [12]. The
other 4 conditions (Fig. 3 A) were biphasic conditions that were
hypothesized to lead to similar expression levels, but potentially
decrease muscle twitching, which is advantageous in keeping good
contact between the tissue and the electrode [18,19]. These conditions were required to keep the same total pulsing time of
1200 ms, as derived from the monophasic Group 1. Group 2 had
a pulsing pattern delivering 600,000 pulses at 40 V for 1 ls, a
biphasic delay of 1 ls, and a second phase of 40 V for 1 ls followed
by a 1 ls pulse gap. Group 3 had a pulsing pattern delivering
30,000 pulses at 40 V for 20 ls, a biphasic delay of 1 ls, and a second phase of 40 V for 20 ls followed by a 1 ls pulse gap. Group 4
had a pulsing pattern delivering 30,000 pulses at 40 V for 1 ls, a
biphasic delay of 1 ls, and a second phase of 40 V for 1 ls followed by a 1 ls pulse gap. Group 5 had a pulsing pattern delivering
12,632 pulses at 150 V for 20 ls for the first phase, a biphasic
delay of 1 ls, and a second phase consisting of 40 V for 75 ls, followed by a 10 ls pulse gap.
2.5. Heart gene electrotransfer

2.7. Immunofluorescence analysis
A left thoracotomy was performed as previously described to
expose left ventricular myocardium [13]. Animals were randomly
assigned to the traditional plasmid, NanoplasmidTM, and IO groups.
A 1 cm2 monopolar platinum non-invasive surface electrode
was used to administer pulses. A metal grounding plate was placed
under the animal on the opposite flank, with electrode gel ensuring
contact between skin and grounding plate. The pulser used was
custom-built, using a power supply manufactured by Advanced
Energy (Fort Collins, CO).
30 ll of 2 mg/ml pDNA was injected in 3 different areas of the
left ventricle to minimize damage to the myocardium. For GET
groups, the electrode was placed on the surface of the left ventricle
near the injection site immediately after injection and pulses were
administered. Pulses were delivered during the rise of the R wave
in the electrocardiogram to avoid fibrillating the heart. 4 square
wave pulses were delivered to each animal and were 100 ms long
with 120 V being administered for the traditional plasmid group
and 90 V being administered for the NanoplasmidTM group. The IO
group did not receive any pulses. These pulsing parameters originated from previous research on GET to the myocardium, however
a different electrode was used in this study and thus the parameters were optimized for this new electrode. Additionally, we
hypothesized based on the previous experiments that the
NanoplasmidTM group could achieve relatively high expression
levels with lower applied voltage of 90 V, than the 120 V required

Immunofluorescence was used to determine the transfection
efficiency of the plasmids. Cells were fixed using a 4%
paraformaldehyde (PFA) solution and the gWiz-Luc-Myc-DDK
and NTC9385R-Luc-Myc-DDK groups were stained for DDK and
counterstained with DAPI. To stain for the DDK protein, a rabbit
monoclonal anti-DDK antibody (TA150078, OriGene, Rockville,
MD) was used and labeled with an AlexaFluor488 conjugated goat
anti-rabbit IgG secondary antibody (A11034, ThermoFisher Scientific, Grand Island, NY). Fluorescent microscopy was used to image
all groups by tiling and stitching together 25 images at a 10X magnification (Fig. 2C, D, G, H). DDK-expressing cells were then
counted using ImageJ (Bethesda, MD) and reported as a percentage
of DDK-positive cells (Fig. 2B, and F).
After 48-hour time point imaging skin samples were harvested
and fixed in a 4% PFA solution. Tissue samples were paraffinembedded and sectioned by IDEXX BioAnalytics (Westbrook,
ME). Hematoxylin and eosin staining was also performed by IDEXX
BioAnalytics. Unstained slides were deparaffinized using CitriSolvTM
(Decon Labs, King of Prussia, PA) and an alcohol gradient. Antigen
retrieval was performed using citric acid (pH 6). To stain for the
DDK protein, a rabbit polyclonal anti-DDK antibody (TA150078,
OriGene, Rockville, MD) was used and labeled with an AlexaFluor488 conjugated goat anti-rabbit IgG secondary antibody
(A11034, ThermoFisher Scientific, Grand Island, NY). Negative con3
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Fig. 2. Reduced vector size significantly increase gene expression in vitro. Gene expression levels at 72 h measured via bioluminescence are significantly higher with reduced
vector size for equal mass transfection (A). Transfection efficiency is significantly increased with reduced vector size for equal mass transfection (B). Immunofluorescence
staining for DDK tag in rat tenocyte transfected with NanoplasmidTM(C) or with traditional plasmid (D) for equal mass transfection. Gene expression levels at 72 h measured
via bioluminescence are significantly higher with reduced vector size for equimolar transfection (E). Transfection efficiency is significantly increased with reduced vector size
for equimolar transfection (F). Immunofluorescence staining for DDK tag in B16F10 cells transfected with NanoplasmidTM(G) or with traditional plasmid (H) for equal mass
transfection. *p < 0.05, **=p < 0.01, ***=p < 0.001.

trol samples did not receive a primary antibody. All samples were
counterstained with DAPI. Fluorescent microscopy was used to
take representative images of the epidermis and muscle layers.
After 48-hour time point imaging heart tissue was harvested
and fixed in a 4% PFA solution. Tissue samples were paraffinembedded and sectioned by IDEXX BioAnalytics (Westbrook,
ME). Hematoxylin and eosin and Masson’s trichrome staining were
also performed by IDEXX BioAnalytics. Unstained slides were
deparaffinized using CitriSolvTM (Decon Labs, King of Prussia, PA)
and an alcohol gradient. Antigen retrieval was performed using
AR6 buffer (Akoya Biosciences, Marlborough, MA). To stain for
the DDK protein, a rabbit monoclonal anti-DDK antibody
(TA150078, OriGene, Rockville, MD) was used and labeled with
an AlexaFluor488 conjugated goat anti-rabbit IgG secondary antibody (A11034, ThermoFisher Scientific, Grand Island, NY). Negative
control samples did not receive a primary antibody. All samples
were counterstained with a mouse monoclonal anti-cardiac troponin I antibody (ab10231, Abcam, Cambridge, MA), labeled with
an AlexaFluor546 conjugated goat anti-mouse IgG secondary antibody (A11030, ThermoFisher Scientific, Grand Island, NY). Slides
were then mounted with Vectashield hardset antifade mounting
medium (H-1400, Vector Laboratories, Burlingame, CA). Fluorescent microscopy was used to take representative images of the epidermis and muscle layers. Slides were imaged with a Leica
Microsystems (Buffalo Grove, IL) DMi8 microscope.

3. Results
3.1. Reporter gene delivery in vitro
Use of the NanoplasmidTM vector delivered in an equal mass as
the gWiz vector, significantly increased gene expression and transfection efficiency when measured via bioluminescence and cell
count (Fig. 2 A-D). An image of a representative plate is shown in
Supplementary Fig. 1.
Equimolar delivery of the NanoplasmidTM vector, compared to
the gWiz vector, significantly increased gene expression and transfection efficiency when measured via bioluminescence and cell
count (Fig. 2 E-H).

3.2. Reporter gene delivery to the skin
Multiple pulsing conditions, as described in Section 2.4 are
shown in Fig. 3A. Briefly, we included a monophasic group that
we have previously observed gene expression in the skin using a
similar condition [12]. The other 4 conditions (Fig. 3 A) are biphasic
conditions that were hypothesized to lead to similar expression
levels, but potentially decrease muscle twitching [18,19].
The monopolar and monophasic control condition (group 1,
Fig. 3A) achieved significantly higher expression in both plasmids
when compared to their respective injection only (IO) groups when
measured via bioluminescence (Fig. 3B). There were no significant
differences in expression in the other groups when compared to
their respective IO groups, nor between the two plasmids. Further
research will be done to improve expression using biphasic
conditions.

2.8. Statistical analysis
All quantitative data were evaluated with a one-way analysis of
variance, with GraphPad Prism8 software.
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Fig. 3. Gene expression in the skin was significantly enhanced with NanoplasmidTM vector. Pulsing conditions by group, showing the first 2 pulses and the last pulse for each
condition (A). Gene expression after GET to the rat skin as measured by bioluminescence (B). For all conditions n = 4.

Cells expressing the DDK tag were observed in the epidermis
(Fig. 4A-B) and muscle layers (Fig. 4C-D) of the skin in both plasmid
groups for group 1, the monopolar and monophasic condition.
Figure Supplementary Fig. 2 shows corresponding negative control
images for epidermis and muscle layers of the skin.

in vitro when transfected using both equal mass and equal
moles. Additionally, we found that up to a 1:5 dilution of the
NanoplasmidTM yielded a successful transfection as defined by
having greater average gene expression measured by bioluminescence and transfection efficiency when compared to the traditional plasmid group. These results warranted further
investigation in vivo.
Previous studies show that gene delivery to the skin via GET is
typically limited to the epidermis [16,21]. One study required heat
to aid GET that resulted in transfected cells within the muscle layer
of the skin [12]. With the NanoplasmidTM and different pulsing
parameters, we were able to transfect the muscle layer via GET
without the use of additional aids.
Further work will be done to optimize biphasic GET pulsing
conditions in skin that result in similar expression levels without
damaging tissue, as only group 1 (monophasic) condition achieved
optimal gene expression levels. Skin damage was not observed for
any of the pulsing groups.

3.3. Reporter gene delivery to the heart
Gene expression levels were significantly increased in the
NanoplasmidTM group at 24 and 48 h after transfection when measured via bioluminescence (Fig. 5 A). Immunofluorescence of both
groups shows DDK tag expression throughout the myocardium
(Fig. 5 B-C).
4. Discussion
Results suggest that decreasing the plasmid backbone length
enhanced gene expression levels and transfection efficiency
5
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Fig. 4. Reduced vector size has comparable expression distribution, as shown with immunofluorescence staining for the DDK tag for monopolar and monophasic GET to the
skin. Abundant expression is observed in the epidermis with NanoplasmidTM (A), epidermis with traditional plasmid (B), skeletal muscle with NanoplasmidTM (C), and skeletal
muscle with traditional plasmid (D).

By utilizing the NanoplasmidTM over a traditional plasmid, significantly higher levels of gene expression can be achieved with a
lower voltage in GET to the myocardium. Previous literature has
established that by lowering voltages used during GET, tissue damage and muscle twitching is reduced [17]. Reducing muscle twitch
is ideal when using GET delivery methods to ensure the electrode
(s) maintains contact with the tissue during pulsing.
In addition, it is important to note that the differences in gene
expression as measured by bioluminescence between the skin
and the myocardium are due to difference in cell/tissue types, as
well as our ability to detect emitted light. When using the IVIS to
measure bioluminescence in the skin, we are able to position the
animal so that the flank with the treatment faces the camera detector without any obstructions. Since the heart is an internal organ,
there are tissues ventral relative to the heart partially obstruct
the signal. Any luminescence emitted from the heart has to travel
through the muscle and bone of the thorax, the overlaying muscle
and connective tissue, and then the entire thickness of the overlaying skin to reach the camera detector. This leads to an overall lower
bioluminescence reading. Therefore, our bioluminescence measurements are intended to compare expression only within the
same tissue type.
NanoplasmidsTM are optimized to be produced in large scales
when compared to traditional plasmids [20]. NanoplasmidsTM are
also antibiotic-free, adhering to European Pharmacopoeia and
European Medicines Agency guidelines [20]. Minicircles, a
higher-expression alternative to traditional plasmids, may suffer
from production and quality issues [3,10], thus creating a need
for pDNA vectors that can provide higher expression than traditional vectors without compromising production scalability.

Reducing plasmid backbone length significantly improved
transgene expression levels in rat tenocytes and rat myocardium.
This enhanced transgene expression was also observed in different
gene delivery methods: a commercially available transfection
reagent and GET. Improved transgene expression levels can aid in
gene therapies in a variety of contexts. Particularly, non-viral gene
transfer methods are often considered safe but have lower transgene expression levels when compared to viral gene transfer methods [2]. Utilizing plasmids with smaller backbone lengths may
allow non-viral gene transfer methods to reach therapeutic transgene expression levels, providing a safe and effect method of gene
transfer.

5. Conclusion
Reducing plasmid DNA backbone length significantly increased
transgene expression levels in vitro in rat tenocytes and in vivo in
rat myocardium. This effect was observed in both GET and a commercially available transfection reagent as gene delivery methods.
The NanoplasmidTM was also able to transfect multiple layers of the
skin, including the muscle, which previously has only been done
with additional aids [12]. Improving transgene expression levels
has a variety of applications in the area of gene therapy.
Declaration of Competing Interest
The authors declare that they have no known competing financial interests or personal relationships that could have appeared
to influence the work reported in this paper.
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